VistaGen Therapeutics Inc (VTGN)

Healthcare | Biotechnology
Income Statement (Quarterly) 2025-06-30 2024-12-31 2024-09-30 2024-06-30
Revenue 244,000 234,000 183,000 84,000
Cost of Revenue 169,000 161,000 0 0
Gross Profit 75,000 73,000 183,000 84,000
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 4,370,000 4,049,000 4,195,000 4,567,000
Operating Expenses 15,879,000 15,354,000 14,410,000 12,215,000
Operating Income -15,804,000 -15,120,000 -14,227,000 -12,131,000
Interest Expense 0 0 0 0
Income Before Tax -15,095,000 -14,089,000 -12,954,000 -10,733,000
Income Tax Expense 0 0 7,000 0
Net Income -15,095,000 -14,089,000 -12,961,000 -10,733,000
Per Share
EPS -0.47 -0.46 -0.42 -0.35
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Revenue 486,000 1,064,000 -227,000 1,108,900 1,089,500
Cost of Revenue 0 0 0 815,200 0
Gross Profit 486,000 1,064,000 -227,000 293,700 0
Operating Expenses
R&D Expenses 0 0 0 0 0
SG&A Expenses 17,084,000 14,063,000 14,664,000 13,248,000 6,547,000
Operating Expenses 55,824,000 34,085,000 59,041,000 48,655,800 19,023,400
Operating Income -55,973,000 -33,021,000 -59,268,000 -47,778,900 -17,933,800
Interest Expense 0 0 23,000 232,000 13,000
Income Before Tax -51,411,000 -29,358,000 -59,242,000 -47,759,000 -17,931,600
Income Tax Expense 7,000 4,000 6,000 3,400 2,600
Net Income -51,418,000 -29,362,000 -59,248,000 -47,762,400 -17,934,200
Per Share
EPS -1.67 -1.52 -8.51 -7.24 -0.21
EPS Diluted 0.00 0.00 0.00 0.00 0.00
Balance Sheet (Quarterly) 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Assets
Cash and Cash Equivalents 67,131,000 119,166,000 16,637,600 68,135,300
Short Term Investments 13,351,000 0 0 0
Net Receivables 0 0 802,700 337,900
Inventory 0 0 -735,600 2,453,000
Total Current Assets 82,076,000 120,672,000 17,507,400 70,998,000
Property Plant Equipment 1,811,000 2,255,000 2,767,600 3,076,300
Goodwill and Intangibles 0 0 0 0
Total Assets 84,341,000 123,653,000 21,089,200 74,643,400
Liabilities
Account Payables 653,000 1,547,000 2,473,100 2,758,600
Short Term Debt 561,000 1,100,000 592,600 433,300
Total Current Liabilities 12,612,000 5,123,000 4,567,400 5,765,100
Long Term Debt 948,000 1,570,000 2,127,200 2,605,400
Total Liabilities 13,951,000 9,367,000 9,009,200 9,928,100
Shareholders Equity
Retained Earnings -407,632,000 -356,214,000 -326,851,700 -267,604,000
Total Shareholders Equity 70,390,000 114,286,000 12,080,000 64,715,300
Balance Sheet (Annual) 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Assets
Cash and Cash Equivalents 67,131,000 119,166,000 16,637,600 68,135,300 103,108,300
Short Term Investments 13,351,000 0 0 0 0
Net Receivables 0 0 802,700 337,900 40,600
Inventory 0 0 -735,600 2,453,000 0
Total Current Assets 82,076,000 120,672,000 17,507,400 70,998,000 104,117,500
Property Plant Equipment 1,811,000 2,255,000 2,767,600 3,076,300 3,587,000
Goodwill and Intangibles 0 0 0 0 0
Total Assets 84,341,000 123,653,000 21,089,200 74,643,400 108,281,300
Liabilities
Account Payables 653,000 1,547,000 2,473,100 2,758,600 838,300
Short Term Debt 561,000 1,100,000 592,600 433,300 367,800
Total Current Liabilities 12,612,000 5,123,000 4,567,400 5,765,100 4,189,000
Long Term Debt 948,000 1,570,000 2,127,200 2,605,400 3,350,800
Total Liabilities 13,951,000 9,367,000 9,009,200 9,928,100 16,302,800
Shareholders Equity
Retained Earnings -407,632,000 -356,214,000 -326,851,700 -267,604,000 -219,841,600
Total Shareholders Equity 70,390,000 114,286,000 12,080,000 64,715,300 91,978,500
Cash Flow Statement (Quarterly) 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Operating Activities
Net Income -51,418,000 -29,362,000 -59,247,700 -47,762,400
Depreciation & Amortization 635,000 568,000 509,800 711,100
Stock Based Compensation 4,315,000 2,182,000 3,336,000 3,480,700
Change in Working Capital 4,760,000 793,000 2,028,200 -1,917,900
Operating Cash Flow -42,097,000 -25,813,000 -49,715,100 -45,256,500
Investing Activities
Capital Expenditure -191,000 -61,000 -212,000 -200,400
Investments -191,000 -61,000 -212,000 -200,400
Investing Cash Flow -13,148,000 -61,000 -740,300 -200,400
Financing Activities
Debt Repayment 0 -985,000 -1,500 -3,000
Common Stock Issued/Repurchased 3,009,000 129,379,000 -180,300 949,379,500
Dividends Paid 0 0 0 -945,100,000
Financing Cash Flow 3,210,000 128,402,000 -1,042,300 10,483,900
Summary
Free Cash Flow -42,288,000 -25,874,000 -49,927,100 -45,456,900
Net Change in Cash -52,035,000 102,528,000 -51,497,701 -34,973,000
Cash Flow Statement (Annual) 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Operating Activities
Net Income -51,418,000 -29,362,000 -59,247,700 -47,762,400 -17,934,200
Depreciation & Amortization 635,000 568,000 509,800 711,100 117,600
Stock Based Compensation 4,315,000 2,182,000 3,336,000 3,480,700 2,306,100
Change in Working Capital 4,760,000 793,000 2,028,200 -1,917,900 3,437,000
Operating Cash Flow -42,097,000 -25,813,000 -49,715,100 -45,256,500 -12,073,500
Investing Activities
Capital Expenditure -191,000 -61,000 -212,000 -200,400 -275,400
Investments -191,000 -61,000 -212,000 -200,400 -275,400
Investing Cash Flow -13,148,000 -61,000 -740,300 -200,400 -275,400
Financing Activities
Debt Repayment 0 -985,000 -1,500 -3,000 -606,400
Common Stock Issued/Repurchased 3,009,000 129,379,000 -180,300 949,379,500 109,474,600
Dividends Paid 0 0 0 -945,100,000 0
Financing Cash Flow 3,210,000 128,402,000 -1,042,300 10,483,900 114,102,100
Summary
Free Cash Flow -42,288,000 -25,874,000 -49,927,100 -45,456,900 -12,348,900
Net Change in Cash -52,035,000 102,528,000 -51,497,701 -34,973,000 101,753,200